Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details) - Level 3 - Elusys Therapeutics $ in Millions	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Revenue earn-out | Discount rate | Discounted cash flow analysis
Fair Value of Financial Instruments
Contingent Consideration	0.140	0.245
Revenue earn-out | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration	141.4
Revenue earn-out | Future revenue projections | Discounted cash flow analysis
Fair Value of Financial Instruments
Contingent Consideration		325.9
Deferred contract consideration | Discount rate | Discounted cash flow analysis
Fair Value of Financial Instruments
Contingent Consideration		0.155
Deferred contract consideration | Future revenue projections | Discounted cash flow analysis
Fair Value of Financial Instruments
Contingent Consideration		7.6